當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院4區(qū) JCRQ2 期刊介紹(非官網(wǎng))

Clinical And Experimental MedicineSCIE

國際簡稱：CLIN EXP MED 參考譯名：臨床和實(shí)驗(yàn)醫(yī)學(xué)

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：1591-8890; E-ISSN：1591-9528; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ITALY; 出版商：Springer International Publishing; 出版語言：English; 出版周期：Quarterly; 出版年份：2001; 研究方向：醫(yī)學(xué)-醫(yī)學(xué)：研究與實(shí)驗(yàn)

評(píng)價(jià)信息：: 影響因子：3.2; H-index：39; CiteScore指數(shù)：4.8; SJR指數(shù)：1.038; SNIP指數(shù)：1.145

發(fā)文數(shù)據(jù)：: Gold OA文章占比：27.58%; 研究類文章占比：67.07%; 年發(fā)文量：246; 自引率：0.0217...; 開源占比：0.2075; 出版撤稿占比：0; 出版國人文章占比：0.34; OA被引用占比：0.1036...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Clinical And Experimental Medicine期刊介紹

Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.

期刊簡介Clinical And Experimental Medicine期刊介紹

《Clinical And Experimental Medicine》自2001出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約2.5月
醫(yī)學(xué)
MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Clinical And Experimental Medicine Cite Score數(shù)據(jù)

CiteScore：4.8
SJR：1.038
SNIP：1.145

學(xué)科類別	分區(qū)	排名	百分位
大類：Biochemistry, Genetics and Molecular Biology 小類：General Biochemistry, Genetics and Molecular Biology	Q2	81 / 221	63%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Clinical And Experimental Medicine 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Clinical And Experimental Medicine JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	81 / 189	57.4%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	84 / 189	55.82%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計(jì)

國家/地區(qū)數(shù)量
CHINA MAINLAND95
Italy33
Poland11
Brazil9
Egypt9
Mexico9
Czech Republic8
Slovakia8
Australia7
Japan7

本刊中國學(xué)者近年發(fā)表論文

1、In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model
Author: Shi, Xiangjun; Wei, Yanzhe; Yao, Xingchen; Du, Boran; Wu, Xiaoguang; Kong, Xiangyu; Du, Xinru

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. 23, Issue 1, pp. 45-54. DOI: 10.1007/s10238-021-00786-w
2、Prognostic value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis
Author: Li, Qian; Hu, Linhui; Charwudzi, Alice; Zhu, Weiwei; Meng, Ye; Zhai, Zhimin

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. 23, Issue 1, pp. 31-43. DOI: 10.1007/s10238-021-00775-z
3、A study of the prognostic value of long non-coding RNA CASC15 in human solid tumors utilizing The Cancer Genome Atlas (TCGA) datasets and a meta-analysis
Author: Chen, Weiwei; Qian, Wenqi; Nie, Jun; Dai, Mintao

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. 23, Issue 1, pp. 65-78. DOI: 10.1007/s10238-021-00789-7
4、Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma
Author: Zhao, Hu; Chen, Yuan; Liao, You-Ping; Chen, Hai-Mei; Yang, Qiu-Hong; Xiao, Yin; Luo, Jing; Chen, Zhen-Zhen; Yi, Lai; Hu, Guo-Yu

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. 23, Issue 1, pp. 55-64. DOI: 10.1007/s10238-022-00805-4
5、Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma
Author: Tan, Xiao-ping; Zhou, Kai; Zeng, Qing-li; Yuan, Yun-fei; Chen, Wei

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. 23, Issue 1, pp. 107-115. DOI: 10.1007/s10238-022-00813-4
6、Distribution and survival outcomes of primary head and neck hematolymphoid neoplasms in older people: a population-based study
Author: Zheng, Yan-Hua; Tian, Biao; Qin, Wei-Wei; Zhu, Qing-Wen; Feng, Juan; Hu, Wu-Yue; Chen, Ren-An; Liu, Li

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10238-023-01069-2
7、Ubiquitin-specific peptidase 1: assessing its role in cancer therapy
Author: Huang, Peng; Wang, YuHan; Zhang, PengFei; Li, Qiu

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10238-023-01075-4
8、Superoxide dismutase 2 as a predictor in patients with hepatitis B virus-associated acute-on-chronic liver failure
Author: Liu, Huihui; Lyu, Hui; Jiang, Xuemei; Wang, Li; Li, Haiming; Wei, Xuefei; Li, Linlin; Zhu, Jinyu; Fan, Yuchen; Wang, Kai

Journal: CLINICAL AND EXPERIMENTAL MEDICINE. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10238-022-00979-x